CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
AssigneeThe Regents of the University of California
InventorSherie L. Morrison
Life of this patent
Estimating the term…
Abstract
In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha.
Claims18
A method of killing or inhibiting growth and/or proliferation of a cell that expresses or overexpresses CD138, said method comprising contacting said cell with a chimeric construct in a therapeutically effective dose, where said construct comprises an interferon alpha attached by a peptide linker to an a full-length antibody that binds CD138, wherein the amino acid sequence of said peptide consists of the sequence SGGGGS (SEQ ID NO:8), and wherein said construct, when contacted to said cell, results in the killing or the inhibition of growth or proliferation of said cell.
Dependencies are inferred from the claim text.